# 2026-12671: Uncle Sam Investigates Germany for Not Paying Enough for New Drugs

2026-12671, Initiation of Section 301 Investigation; Hearing; and Request for Public Comments: Germany's Persistent Underpayment for Innovative Pharmaceutical Products, is a Federal Register notice from Trade Representative, Office of United States published 2026-06-24, effective 2026-06-18; PRIA reads it as touching household money (as of 2026-07-01).

- Canonical: https://policyrisk.com/federal-register/2026-12671
- As of: 2026-07-01
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-12671
- Title: Initiation of Section 301 Investigation; Hearing; and Request for Public Comments: Germany's Persistent Underpayment for Innovative Pharmaceutical Products
- Type: Notice
- Agencies: Trade Representative, Office of United States
- Citation: 91 FR 38072
- Published: 2026-06-24
- Effective: 2026-06-18
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-07-01

## In one line

Uncle Sam Investigates Germany for Not Paying Enough for New Drugs

## Summary

The U.S. is launching an investigation into Germany for not paying enough for new, innovative medicines. This could lead to changes in trade rules and possibly impact drug prices or tariffs. Public comments and a hearing will happen between June and September 2026, so everyone affected—especially pharmaceutical companies and patients—should pay attention!

## Abstract

The United States Trade Representative (U.S. Trade Representative) has initiated an investigation pursuant to the Trade Act of 1974, as amended (Trade Act), with respect to Germany's persistent underpayment for innovative pharmaceutical products. The inter-agency Section 301 Committee is holding a public hearing and seeking public comments in connection with this investigation.

## Effects PRIA read

- U.S. opens trade probe; tariffs possible: mixed, medium. On June 18, 2026 the U.S. Trade Representative opened a Section 301 investigation into Germany for underpaying for innovative medicines. USTR is considering whether to take action, and the agency specifically asked commenters to consider tariff and non‑tariff actions as possible responses.
- U.S. patients pay ~3.9× German prices: cost, high. USTR states that U.S. consumers pay approximately 3.9 times as much as consumers in Germany for brand‑name drugs. USTR says this price gap results in the United States bearing a disproportionate share of global pharmaceutical R&D costs.
- Germany ties confidentiality to 9% discount: cost, medium. USTR says Germany conditions confidentiality of manufacturers' pharmaceutical pricing on criteria that include acceptance of a 9 percent price discount and payment of additional administrative costs. USTR is examining this practice as one means by which Germany implements its pricing policies.
- Draft German rebate could reach 20% by 2030: cost, medium. In 2026 Germany introduced draft legislation that would impose an additional mandatory rebate for patented medicines starting in 2027: a fixed 3.5 percent rate for the first half of 2027 and thereafter a variable rate tied to expenditures, with one estimate projecting the dynamic rebate could reach…

## Related documents

- [2026-20615](https://policyrisk.com/federal-register/2026-20615): Request for Comments on the Effect of the European Union's Carbon Border Adjustment Mechanism and the Proposals To Expand Coverage on U.S.…, 2026-10-08
- [2026-20510](https://policyrisk.com/federal-register/2026-20510): Continuation of Actions: China's Acts, Policies, and Practices Related to Technology Transfer, Intellectual Property, and Innovation, 2026-10-07
- [2026-20511](https://policyrisk.com/federal-register/2026-20511): Notice of Conforming Amendment to Product Exclusion: China's Acts, Policies, and Practices Related to Technology Transfer, Intellectual Pro…, 2026-10-07
- [2026-19399](https://policyrisk.com/federal-register/2026-19399): Fiscal Year 2027 Tariff-Rate Quota Allocations for Raw Cane Sugar, 2026-09-23
- [2026-17925](https://policyrisk.com/federal-register/2026-17925): Notice of Conforming Amendments to Product Exclusions: China's Acts, Policies, and Practices Related to Technology Transfer, Intellectual P…, 2026-09-02
- [2026-15181](https://policyrisk.com/federal-register/2026-15181): Notice of Actions in Section 301 Investigations of Acts, Policies, and Practices of Various Economies Related to the Failure of Each Econom…, 2026-07-28

## Sources
- [2026-12671 on federalregister.gov](https://www.federalregister.gov/documents/2026/06/24/2026-12671/initiation-of-section-301-investigation-hearing-and-request-for-public-comments-germanys-persistent)
- [2026-12671 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-06-24/pdf/2026-12671.pdf)

## Related
- [Previous: 2026-12668, Test of the New Electronic Informal Entry Process for Mail](https://policyrisk.com/federal-register/2026-12668)
- [Next: 2026-12672, Hours of Service of Drivers: Association of American Railroads and American Sho…](https://policyrisk.com/federal-register/2026-12672)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-12671 (as of 2026-07-01).